Capital Pro-Égaux Inc announces certain developments in legal
proceedings against Nobel Biocare
LACHENAIE, QC,
Jan. 21, 2013 /CNW Telbec/ - Capital
Pro-Égaux Inc. (the "Company") (NEX: CPE.H) announces that its US
counsels have been advised that a judge of the Eastern District of
Virginia, Alexandria Division, has granted all of Nobel
Biocare's motions for summary judgment of non-infringement. Such
motions were filed by Nobel in response to the Company's
proceedings for patent infringement undertaken against Nobel in the
summer of 2012 as described in the Company's Management Discussion
and Analysis for the six-month period
ended August 31, 2012. The details of the judgment
have not yet been received but, based on our attorneys' preliminary
input, it is likely that the Company will be appealing this
decision in due course.
Caution regarding forward-looking statements
This news release contains certain
forward-looking statements regarding the Company's expectation of
certain future legal actions in connection with the proceedings
against Nobel. Such expectations are based on certain assumptions
based on currently available information. Depending on new
information and further analysis, the Company may change its plans.
The Company disclaims any intention or obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, other than
as required by securities laws.
About Pro-Égaux Inc.
Pro-Égaux through its wholly owned subsidiary,
Technique d'usinage Sinlab Inc., is a company based in Lachenaie, Quebec, specializing mainly in the
conception and design of titanium products to be used in the dental
prosthesis restoration industry.
Neither NEX, the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of NEX and the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE CAPITAL PRO-EGAUX INC.